Desjardins expands health coverage with OncoHelix partnership to enhance cancer care access

Insurers are increasingly integrating medical innovation into their benefits programs

Desjardins expands health coverage with OncoHelix partnership to enhance cancer care access

Life & Health

By Josh Recamara

Desjardins Insurance is expanding its group benefits offering through a new partnership with precision diagnostics firm OncoHelix, giving eligible members access to advanced genomic cancer testing as part of its Cancer Care Focus initiative.

The move highlights how insurers in Canada are increasingly integrating medical innovation into their benefits programs to support early detection, improve treatment outcomes, and reduce long-term health costs.

Under the agreement, Desjardins group insurance members and their dependents will receive coverage for OncoHelix's comprehensive genomic profiling tests, including liquid biopsy, a blood-based testing option that can identify tumor-driving mutations and help clinicians select targeted therapies or clinical trials.

The partnership underscores the growing role of private insurers in filling diagnostic and care gaps left by the public system, where access to biomarker testing can vary significantly across provinces. By extending coverage for these advanced diagnostics, Desjardins aims to help members benefit from early intervention and personalized care that could improve recovery outcomes and reduce the overall cost burden of cancer treatment.

Neda Nasseri, product director of drug insurance at Desjardins Insurance, said the collaboration reflects the insurer’s commitment to integrating innovative health solutions into its coverage portfolio. She noted that providing access to precision diagnostics supports a more holistic approach to cancer care, one that addresses physical, emotional, and financial challenges for plan members and their families.

For OncoHelix, the partnership with one of Canada’s largest insurers marks a significant step toward expanding access to genomic testing nationwide. Pinaki Bose, executive vice president of OncoHelix, said the collaboration will help bring cutting-edge molecular testing closer to patients and physicians, enabling more informed and timely treatment decisions.

This initiative adds to Desjardins’ growing network of health technology partnerships, including Sword Health for AI-guided physiotherapy and Constant Health for digital nutrition coaching.

Together, these collaborations signal a shift in the Canadian insurance landscape, as providers increasingly move beyond traditional risk coverage to deliver integrated health management solutions that support prevention, early diagnosis, and recovery.

Related Stories

Keep up with the latest news and events

Join our mailing list, it’s free!